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The immunosuppressive regimens currently used in transplantation to prevent allograft
destruction by the host’s immune system have deleterious side effects and fail to control
chronic rejection processes. Induction of donor-speciﬁc non-responsiveness (i.e., immuno-
logical tolerance) to transplants would solve these problems and would substantially
ameliorate patients’ quality of life. It has been proposed that bonemarrow or hematopoietic
stem-cell transplantation, and resulting (mixed) hematopoietic chimerism, lead to immuno-
logical tolerance to organs of the same donor. However, a careful analysis of the literature,
performed here, clearly establishes that whereas hematopoietic chimerism substantially
prolongs allograft survival, it does not systematically prevent chronic rejection. Moreover,
the cytotoxic conditioning regimens used to achieve long-term persistence of chimerism
are associated with severe side effects that appear incompatible with a routine use in
the clinic. Several laboratories recently embarked on different studies to develop alterna-
tive strategies to overcome these issues. We discuss here recent advances obtained by
combining regulatory T cell infusion with bone-marrow transplantation. In experimental
settings, this attractive approach allows development of genuine immunological tolerance
to donor tissues using clinically relevant conditioning regimens.
Keywords: transplantation tolerance, hematopoietic chimerism, regulatoryT lymphocytes, passive tolerance, active
tolerance, chronic rejection
INTRODUCTION
The immunosuppressive regimens developed since the discovery
of cyclosporine A showed ever increasing efﬁciency in reducing
the severity and occurrence of acute rejection episodes. Recently,
a systematic analysis of the literature ﬁrmly identiﬁed acute rejec-
tion events as a bad prognosis factor for long-term graft survival
(Wu et al., 2009). Since immunosuppressive drugs efﬁciently con-
trol acute rejection, this explains how they signiﬁcantly improved
allograft survival over the past 40 years despite failing to have a
direct impact on chronic rejection. The failure of current treat-
ments to control chronic rejection processes combined with their
deleterious side-effects urgently call for development of novel ther-
apies against allograft rejection (Kahan, 2003; Meier-Kriesche and
Kaplan, 2011).
During lymphocyte development in primary lymphoid organs,
and due to the random rearrangement of genes encoding the anti-
gen receptor,many autospeciﬁc T and B cell precursors arise. Since
such cells would cause devastating autoimmune pathology, the
natural mechanisms involved in the induction of self-tolerance
play a crucial role in the survival of the species (Waldmann,
2010). Self-tolerance is deﬁned as a state in which autoim-
mune attack is either prevented or deviated to non-detrimental
responses (Walker and Abbas, 2002; Hogquist et al., 2005). It
allows development of protective immunity and is therefore very
speciﬁc. It appears very attractive to manipulate the mechanisms
involved in self-tolerance in order to make them prevent allograft
rejection. If successful, this would allow for indeﬁnite survival of
grafts.
TOLERANCE-INDUCTION BY CELLS OF HEMATOPOIETIC
ORIGIN: PROOF OF PRINCIPLE
Several layers of complementary mechanisms ensure tolerance to
self-antigens. Interestingly, considerable insight into these mech-
anisms was obtained through transplantation models and by
manipulating the development of the immune system early in life,
during embryogenesis or in neonates. Owen (1945) ﬁrst observed
that dizygotic twin cattle, that almost invariably develop placental
anastomosis, “have identical blood types” as adults and he con-
cluded “the critical interchange is of embryonal cells ancestral
to the erythrocytes”. Later, Billingham, Medawar, and colleagues
showed that these chimeric twins “accepted” each other’s skins
when grafted later in life (Billingham et al., 1952). In a 1953 land-
mark paper, the same group showed that skin allograft survival
could be substantially prolonged by injecting a single-cell sus-
pension of donor tissues in utero or into neonates (Billingham
et al., 1953). Such treatment led to varying levels of hematopoi-
etic chimerism, which was later shown to be critically involved in
allograft survival (Lubaroff and Silvers, 1973; Wood and Streilein,
1982; Wren et al., 1993; Alard et al., 1995).
In the two systems described above, lymphocytes developed in
the presence of (and thus learned to be tolerant to) donor antigens.
However, in adults the situation ismore complicated as, in addition
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to developing lymphocytes,preexistingdonor-speciﬁcmature cells
would also need to be rendered tolerant. To bypass this concern,
several laboratories decided to deplete the pool of mature T cells
(Main and Prehn, 1955; Trentin, 1956; Brocades Zaalberg et al.,
1957). These groups ﬁrst experimented this approach through
the elimination of all hematopoietic cells. Recipient mice were
lethally irradiated or treated with cytotoxic drugs, reconstituted
with donor bone marrow, and grafted with skin. These strate-
gies invariably led to substantially increased survival of homo-
and xenografts. More recently, Ildstad and Sachs (1984) deﬁnitely
validated these observations by inducing long-term survival of
allogenic and xenogenic skin grafts using a comparable approach.
Similar results were obtained in the rat for heart and skin grafts
(Colson et al., 1995b; Orloff et al., 1995). Combined, these obser-
vations clearly demonstrated that hematopoietic chimerism leads
to prolonged survival of allografts.
CELLS OF HEMATOPOIETIC ORIGIN INDUCE T CELL
TOLERANCE BY INDUCTION OF APOPTOSIS AND ANERGY
To address the question of how cells of hematopoietic origin
induce tolerance, researchers needed a means to identify T cell
precursors speciﬁc for a given antigen. Kappler et al. (1987b)
showed that practically all T cells expressing the variable TCR
segment Vβ17a, representing up to 15% of the T cell repertoire
in certain mouse-strains, recognized the MHC class II mole-
cule I-E. Given that they had developed an antibody against this
Vβ domain, the mechanisms involved in T cell tolerance to I-E
could now be analyzed. It was shown in I-E expressing mice that
Vβ17a+ T cell precursors were eliminated at an immature stage
during thymic development (Kappler et al., 1987a). The follow-
ing year, the same authors further characterized this mechanism
and showed that clonal deletion requires the expression of the
negatively selecting ligand by thymic cells of hematopoietic origin
(Kappler et al., 1988). Many other illustrations of clonal deletion
of T cells expressing given TCR Vβ segments by endogenous or
exogenous superantigens have since been published (MacDonald
et al., 1988b; Luther and Acha-Orbea, 1997).
Could thymic elimination of reactive clones also be involved in
the neonatal induction of tolerance to alloantigens? This ques-
tion was addressed by MacDonald et al. (1988a) who showed
that the transfer of superantigen-expressing spleen cells into
neonates lead to the intrathymic deletion of superantigen-reactive
T cells. Similar conclusionswere rapidly drawnbyothers (Streilein,
1991). Later, intrathymic deletionof donor-speciﬁc precursorswas
also reported in adult mixed hematopoietic chimeras using TCR
transgenic cells as a tracer population (Manilay et al., 1998).
Thus, thymic cells of hematopoietic origin are involved in dele-
tion of autospeciﬁc T cell-precursors and mixed hematopoietic
chimerism leads to deletion of alloreactive cells. Using thymic
organ cultures to analyze the involvement of different stromal
cells, it was shown that dendritic cells (DC) are critically involved
in this process (Matzinger and Guerder, 1989; Jenkinson et al.,
1992; Anderson et al., 1998). This was further conﬁrmed using
a transgenic mouse model in which TCR ligand-expression was
essentially restricted to DC using the CD11c promoter (Brocker
et al., 1997). Among the thymic DC subtypes, both Sirpα+
and Sirpα − conventional DC have been implicated in central
tolerance-induction by deletion (Wu and Shortman, 2005; Baba
et al., 2009). However, other populations of hematopoietic cells
may also play a role in this process, including CD4+CD8+ thymo-
cytes, thymic macrophages and B cells (Pircher et al., 1992, 1993;
Kleindienst et al., 2000), and circulating peripheral DC (Bonasio
et al., 2006).
Combined, the data discussed thus far showed that DC, and
potentially other cells of hematopoietic origin, contribute to tol-
erance induction by elimination of developing thymocytes. Using
conditioning regimens that totally deplete host T cells before bone-
marrow transplantation, it was proposed that this mechanism was
necessary and sufﬁcient for maintenance of tolerance and that
peripheral mechanisms do not contribute to this process (Khan
et al., 1996). However, other mechanisms could be involved when
less aggressive regimens are used. In normal mice, it has been pro-
posed that deletion of autospeciﬁc T cells that escaped thymic
selection could also occur in peripheral lymphoid organs and
could be involved in the maintenance of self-tolerance (Russell,
1995). To test if similar mechanisms were involved in induction
of tolerance to alloantigens following bone-marrow transplan-
tation, Wekerle et al. (1998) tracked T cells speciﬁc for a given
superantigen in thymectomized mice transplanted with allogeneic
bone-marrow under cover of CTLA4-Ig and antibody to CD154
(“co-stimulatory blockade”). They observed a rapid deletion of
donor-speciﬁc host T cells from the peripheral CD4+ compart-
ment. This observation was later conﬁrmed using a TCR trans-
genic mouse model (Kurtz et al., 2004) and it was further shown
that peripheral deletion relies essentially on two types of mecha-
nisms: activation-induced cell death, a Fas-dependent process that
can be promoted by IL-2 and that leads to apoptosis of activated
T cells when restimulated with high doses of antigen (Lenardo,
1991; Ju et al., 1995; Russell, 1995); and passive cell death or death
“by neglect,” a Fas-independent process that can be prevented by
overexpression of Bcl-2 or Bcl-xL and that leads to T cell apoptosis
when stimulated with low dose of antigen and/or in the absence
of co-stimulatory signals (Boise et al., 1995; Van Parijs et al., 1996;
Wekerle et al., 2001). It was also shown that in addition to DC,
other populations of hematopoietic cells such as B cells have the
capacity to delete allospeciﬁc precursors from the peripheral T cell
compartment (Fehr et al., 2008a,b). Finally, hematopoietic cells
can also cause T cell tolerance by inducing a non-responsive state
called clonal anergy (Rammensee et al., 1989; Tomita et al., 1994;
Hawiger et al., 2001). Combined, the cited reports clearly show
that cells of hematopoietic origin can induce “passive” tolerance
(i.e., apoptosis and anergy).
CAN HEMATOPOIETIC CELLS INDUCE ACTIVE REGULATORY
MECHANISMS?
T lymphocytes from chimeric mice in which radioresistant cells
express MHC molecules but hematopoietic cells do not, vigor-
ously react to self-antigens in vitro (vanMeerwijk andMacDonald,
1999) and in some well-deﬁned experimental conditions in vivo
(Hudrisier et al., 2003). Combined with the observations listed
above, this shows that hematopoietic cells play a central role in
the deletion and/or functional inactivation of self-reactive pre-
cursors. However, passive mechanisms are not sufﬁcient to fully
control self-reactivity. Individuals carrying a mutated FOXP3 gene
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develop the rapidly lethal autoimmune syndrome immuno dys-
function, polyendocrinopathy, enteropathy, X-linked (IPEX). This
is explained by the fact that Foxp3 is required for the program-
ming of a population of regulatory CD4+ T lymphocytes (Treg)
that inhibit and/or divert innate and adaptive immune responses,
mainly those directed against self-antigens. Genuine tolerance to
self, and consequently probably to non-self-antigens, therefore
requires Treg (Fontenot and Rudensky, 2005; Sakaguchi et al.,
2006; Shevach et al., 2006).
Given their central (though not exclusive) role in the control
of autoimmune responses, it was probably not a very surprising
ﬁnding that the Treg repertoire is strongly enriched in autospeciﬁc
cells (Romagnoli et al., 2002; Hsieh et al., 2004). Development
of self-antigen-speciﬁc Treg in the thymus depends on inter-
action of developing precursors with MHC/self-peptide ligands
expressed by thymic epithelial cells (Bensinger et al., 2001; Romag-
noli et al., 2005; Ribot et al., 2006, 2007; Aschenbrenner et al.,
2007). Moreover, the transplantation of allogeneic thymic anla-
gen (i.e., the initial cluster of pluripotent embryonic cells from
which the thymus will develop) into mice induces Treg-mediated
tolerance to subsequent skin grafts of the same donor, again
showing that thymic epithelial cells can select antigen-speciﬁc
Treg (Le Douarin et al., 1996). However, the capacity to trigger
Treg differentiation in the thymus is not a property restricted to
epithelial cells as it has been reported that thymic DC are also
involved in this process (Watanabe et al., 2005; Proietto et al.,
2008; Wirnsberger et al., 2009). Moreover, induction of Treg dif-
ferentiation by DC has also been reported in peripheral lymphoid
organs under certain carefully controlled experimental condi-
tions (reviewed by Romagnoli et al., 2008). It may therefore be
hypothesized that hematopoietic chimerism can lead to differ-
entiation and/or expansion of Treg speciﬁc for donor antigens
and thus to the development of dominant tolerance. However,
in experimental systems where the conditioning regimen used to
induce mixed hematopoietic chimerism involved the total dele-
tion of host T cells, transfer of syngeneic naïve CD4+ T cells
into the recipient leads to bone-marrow rejection and to the con-
comitant loss of donor-speciﬁc transplantation tolerance (Wren
et al., 1993). This result clearly demonstrated that hematopoi-
etic chimerism per se is insufﬁcient for induction of dominant
tolerance to alloantigens. Given the non-redundant role of Treg
in maintenance of self-tolerance, hematopoietic chimerism there-
fore appears unlikely to be sufﬁcient for permanent survival of
allografts.
Active tolerance mechanisms are not limited to those medi-
ated by Treg. “Immune deviation” from a harmful Th1 to a less
detrimental Th2 response has also been shown to play a role in
control of immune responses (Rocken, 1996; Walker and Abbas,
2002). Alloreactive Th2 cytokine producing T cells have been
observed after neonatal injection of lymphohematopoietic cells
(Streilein, 1991) and immune deviation by IL-4 was shown to play
a critical role in tolerance to alloantigens (Donckier et al., 1995).
Thehematopoietic (micro-)chimerism induced in this experimen-
tal model, which is critically required for the allograft tolerance
(Lubaroff and Silvers, 1973), therefore appears to induce an active
regulatory mechanism. However, this mechanism appears insufﬁ-
cient for induction of full immunological tolerance to alloantigens
(see below). Stem-cell transplantation under cover of cyclophos-
phamide can induce tolerance to MHC-matched skin allografts
in mice. It was shown that NKT cells, another immunoregula-
tory population, play a central role in this phenomenon (Iwai
et al., 2006). Regulatory T cell populations other than Foxp3+ cells
may therefore be induced by hematopoietic chimerism but their
activity appears insufﬁcient for prevention of chronic allograft
rejection.
DOES HEMATOPOIETIC CHIMERISM INDUCE GENUINE
TOLERANCE TO ALLOGRAFTS?
As discussed above, hematopoietic chimerism is thought to be
sufﬁcient for induction of tolerance to allografts. The mechanisms
involved include central and peripheral clonal deletion and anergy.
After the initial reports on allograft tolerance in dizygotic cattle
twins that had shared blood circulation during embryonic life, it
became clear that most skin grafts were rejected in the long term
(Stone et al., 1965, 1971). Second skin grafts from the same donor
survived less long than the ﬁrst grafts, but substantially longer than
third party organs, showing that the tolerance mechanism had not
waned away.
Also neonatal injection of allogeneic splenocytes, leading to
hematopoietic microchimerism, is thought to induce tolerance to
subsequent skin grafts. However, this procedure appeared to work
only in a limited number of donor/host combinations. Impor-
tantly, most of the reported donor/host combinations concerned
MHC congenic strains (i.e., expressing distinct MHC haplotypes
on an identical genetic background) and chronic rejection was
not systematically studied (Streilein and Klein, 1977). Moreover,
even when acceptance of skin allografts was achieved, it did not
correlate with immunological unresponsiveness (Streilein, 1991;
Donckier et al., 1995).
In adult mice, lymphoablation was achieved using lethal
total body irradiation or depleting antibodies to, e.g., CD4 and
CD8. Myeloablation, required for induction of hematopoietic
chimerism, was induced by the irradiation or administration of
myeloablative drugs. Subsequent transplantation of allogenic or
xenogenic bone marrow led to persistent chimerism (reviewed in
Wekerle and Sykes,1999;Cosimi and Sachs,2004). Skin grafts from
the bone-marrow donors could survive for prolonged periods, but
success-rates were often well below 100% and chronic rejection
was not studied. In some host/donor combinations, hematopoi-
etic chimerism failed to prevent acute rejection of skin allografts
(Boyse et al., 1970), and T cell reactivity to skin-speciﬁc anti-
gens not expressed by hematopoietic cells was responsible for this
observation (Scheid et al., 1972; Boyse et al., 1973). Also the sur-
vival of cardiac allografts was favored by hematopoietic chimerism
(Steinmuller and Lofgreen, 1974). However, histological analysis
of surviving hearts revealed frequent chronic rejection (Russell
et al., 2001). Also in the rat, myelo- and lymphoablation followed
by induction of hematopoietic chimerism was reported to pro-
long survival of skin, heart, and renal allografts (Slavin et al., 1978;
Colson et al., 1995b; Orloff et al., 1995; Blom et al., 1996). How-
ever, chronic rejection was seldom adequately studied. It appears
therefore that immunological tolerance to allografts is not sys-
tematically achieved by induction of hematopoietic chimerism in
lymphoablated recipients.
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Hematopoietic chimerism can also be induced with non-
lymphoablative regimens. Surprisingly,under certain of these con-
ditions, allografts appear to do better than when lymphoablative
conditioning is used (Table 1). Blocking the T cell co-stimulatory
molecule CD28 with an Ig-fusion protein of its CTLA4-ligand
(CTLA4-Ig), combined with inhibition of the CD40/CD40L (i.e.,
CD154) pathway involved in activation of antigen presenting and
B cells, substantially prolongs heart and skin allograft survival
(Larsen et al., 1996). However, histological signs of chronic rejec-
tion of cardiac allografts was observed in all thus conditioned mice
(Shirasugi et al., 2002). When co-stimulatory blockade was com-
bined with induction of hematopoietic chimerism, heart, skin,
and also intestine allografts survived substantially longer and no
chronic rejection was observed (Wekerle et al., 1998, 2000; Adams
et al., 2001; Shirasugi et al., 2002;Guo et al., 2003). Transplantation
tolerance in such settings was dominant and depended on Treg, at
least during early stages (Bigenzahn et al., 2005; Domenig et al.,
2005).
Combined, these data indicate that hematopoietic chimerism
per se appears insufﬁcient for induction of transplantation tol-
erance. However, when combined with conditioning regimens
that allow for development of dominant tolerance, prevention of
chronic rejection can be achieved.
INDUCTION OF HEMATOPOIETIC CHIMERISM: TOWARD THE
CLINIC
Given the very encouraging results obtained with mixed
hematopoietic chimerism in rodents, several groups have
attempted to induce hematopoietic chimerism and transplanta-
tion tolerance in large animal models (Wekerle and Sykes, 1999;
Cosimi and Sachs, 2004; Horner et al., 2006). Experimental proto-
cols are necessarilymore complex than in rodents since adult recip-
ients were used and high dose whole body irradiation is associated
with a too high level of morbidity. A combination of immunosup-
pressive drugs and antibodies, as well as lower levels of irradiation
or irradiation limited to lymphoid organs, was therefore used as
conditioning regimen (Table 2). In miniature swine, a precondi-
tioning of T cell depletion, low dose total body irradiation, thymic
irradiation, and splenectomy, followed by bone-marrow and skin
transplantation, led to persistent hematopoietic chimerism in ﬁve
out of six animals. Four of these animals were transplanted with
donor skin. Half of these animals appeared to accept, but the other
half rejected the skin allografts (Fuchimoto et al., 2000). Also using
amilder conditioning regimen,persistent chimerismwas obtained
in miniature swine and one out of two skin grafts appeared to be
permanently accepted (Fuchimoto et al., 2000). When the latter
protocol was used for kidney transplantation, four out of four
allografts survived more than 100 days (Fuchimoto et al., 2000,
2001). Therefore, as observed in rodents, persistent hematopoietic
chimerism led to an incomplete level of allograft tolerance that
appeared efﬁcient for protection of poorly immunogenic organs
such as kidneybut fails to prevent rejectionof highly immunogenic
skin allografts.
In Cynomolgus monkeys, a preconditioning regimen was used
that consisted of T cell depletion, low dose total body irradi-
ation, thymic irradiation, and splenectomy, followed by bone-
marrow and kidney transplantation (Kawai et al., 1995, 2002, 2004;
Kimikawa et al., 1997b). Only transient hematopoietic chimerism
was observed, but nevertheless 8 out of 15 grafts did not show
signs of rejection (Table 2). An acute cellular rejection process led
to the loss of the other grafts (Kimikawa et al., 1997a; Kawai et al.,
1999). A similar preconditioning regimen was used for monkeys
that received a cardiac allograft. Three out of ﬁve animals devel-
oped transient chimerism, but all ﬁve hearts were eventually lost
by a rejection-process characterized by cellular inﬁltrates (Kawai
et al., 2002). The observation that kidney allografts were more
likely to be accepted than heart allografts conﬁrmed earlier data on
transplantation in miniature swine that, interestingly, also showed
that kidneys can play an important role in tolerance to heart allo-
grafts (Madsen et al., 1998;Mezrich et al., 2003a,b). Taken together
these data highlight the difﬁculty to obtain an efﬁcient and per-
sistent engraftment of hematopoietic stem cells in large animal
models. When only transient, hematopoietic chimerism induces
tolerance mechanisms that are probably different from and less
efﬁcient than those induced in hosts with long-term persistence of
hematopoietic donor cells.
INDUCTION OF HEMATOPOIETIC CHIMERISM: IN THE CLINIC
Based on the promising results in monkeys, induction of
hematopoietic chimerism for prevention of allograft rejection has
also been performed in humans (Table 3). Infusion of donor
bone-marrow showed some beneﬁcial effect in renal allograft
recipients (Monaco, 2003). Interestingly, in an early report in
which large numbers of patients were described, infusion of
donor bone marrow, leading to transient chimerism, inhibited
acute but not chronic rejection (Barber et al., 1991; McDaniel
et al., 1994). One of the ﬁrst reported cases of long-term allograft
survival achieved by induction of hematopoietic chimerism con-
cerned awomanwith end-stage renal disease secondary tomultiple
myeloma (Spitzer et al., 1999). The patient received an immuno-
suppressive but non-myeloablative conditioning regimen. HLA-
matched bone marrow and kidney from the patient’s sister were
transplanted and the immunosuppressive drug cyclosporine A
administered for 73 days. Whereas the hematopoietic chimerism
disappeared after discontinuation of immunosuppression, the
kidney remained functional for at least another 7 years (Fud-
aba et al., 2006). In total, six multiple myeloma patients receiv-
ing this treatment have been reported and all maintained renal
function after discontinuation of immunosuppression for 2–
7 years (Spitzer et al., 1999; Buhler et al., 2002; Fudaba et al.,
2006). Stem-cell transfusion was also shown to have a beneﬁ-
cial effect in liver transplantation (Donckier et al., 2004). Another
example concerned a patient with end-stage renal disease who
received anHLA-matchedkidney graft. The conditioning regimen,
which included total lymphoid irradiation, immunosuppression,
and a graft of mobilized CD34+ stem cells, led to persistent
hematopoietic chimerism. At the time of publication, the renal
graft had remained functional for 34months (Scandling et al.,
2008).
Induction of hematopoietic chimerism followed by kidney
transplantation was also performed with HLA single haplotype
mismatched grafts (Kawai et al., 2008), a clinically important
setting. Five patients with end-stage renal disease received an
immunosuppressive but non-myeloablative preparative regimen
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Table 1 | Combined bone-marrow and organ transplantation in the mouse: non-myelo- and lymphoablative procedures.
BM/SC graft=>
host
Organ/tissue
graft
Conditioninga Hematopoietic
chimerismb
Allograft survival Reference
ANTIBODIES
No BM, C3H host BALB/c heart αCD154 and
CTLA4-Ig
7/7>day 70 (no
chronic rejection at
d63)
Larsen et al. (1996)
BALB/c skin 15/15>day 50 (no
chronic rejection at
day 50)
B10.A=>B6 B10.A skin αCD154 and
CTLA4-Ig
Persistent 8/8 at day 145 Wekerle et al. (2000)
Transient 1/5 at day 145
B10.A=>B6 B10.A skin αCD154 and
CTLA4-Ig,
sublethal TBI
Persistent 7/9 at day 160 Wekerle et al. (1998)
BALB/c=>B6 BALB/c skin αCD154 and
CTLA4-Ig, BUS
Persistent 7/7 at day 250 Adams et al. (2001)
BALB/c=>B6 BALB/c heart αCD154 and
CTLA4-Ig
Undetectable 8/9 at day 180,
chronic rejection at
day 300 in 8/8
hosts
Shirasugi et al. (2002)
αCD154 and
CTLA4-Ig, BUS
Persistent 5/5 at day 180, no
chronic rejection at
day 300
BALB/c=>B6 BALB/c
intestine
αCD154 and
CTLA4-Ig, BUS
Persistent 5/7 at day 92 Guo et al. (2003)
BALB/c=>B6 BALB/c skin αCD154 and
CTLA4-Ig, Rapa,
Treg
Persistent? 7/7 at day 170 Pilat et al. (2010)
BALB/c=>B6 BALB/c skin low doseTBI,
αCD154
Persistent 0/4 at day 60 Luo et al. (2007)
B6.C-H-2d skin 4/4>day 180
BALB/c=>B6 BALB/c skin αCD154
andαLFA-1
Persistent 4/7>day 270 Metzler et al. (2004)
αCD154 and Rapa 4/7>day 226
αCD154 and BUS
and various
22/24: chronic
rejection
BALB/c heart 4/24: mild chronic
rejection
BALB/c skin αLFA-1 and Rapa 0/6 day 117
BALB/c=>B6 BALB/c
pancreatic
islets
Rapa, low dose
TBI
Persistent 6/6>day 100 Luo et al. (2005)
B10.BR=>CBA B10.BR skin αCD4
andαCD8(nd)
Persistent 8/8 at day 240 Qin et al. (1990)
B10 DST=>C3H C3H heart αCD4(nd) N/D 7/7 at day 100 Pearson et al. (1992)
DRUGS
BALB/c=>B6 BALB/c skin SC, CP, αThy1 Persistent 10/15 at day 159 Mayumi and Good (1989)
BALB/c=>C3H BALB/c skin 7/8 at day 165
B6=>C3H B6 skin 4/9 at day 185
C3H=>B6 C3H skin 0/19 (chronic
rejection)
B10.BR or
BALB/c=>B10
B10.BR or
BALB/c skin
Sublethal TBI, CP Persistent 9/10 at day 60 Colson et al. (1995a)
(Continued)
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Table 1 | Continued
BM/SC graft=>
host
Organ/tissue
graft
Conditioninga Hematopoietic
chimerismb
Allograft survival Reference
BALB/c=>B10 BALB/c heart 6/6>day 420
B10.A(5R)=>B10 B10.A(5R) skin SC, CP Transient 4/10 at day 200 Tomita et al. (1990b)
C3H=>AKR C3H skin SC, CP Transient 5/8 at day 100=> Tomita et al. (1990a)
B10.BR=>AKR B10.BR skin 5/6 at day 100
AKR=>C3H AKR skin 5/8 at day 100
B10.BR=>C3H B10.BR skin 4/8 at day 100
B10.D2=>BALB/c B10.D2 skin 5/6 at day 100
B10=>AKR B10 skin 0/6 at day 12
B6=>C3H B6 skin 0/6 at day 13=>
B6=>AKR B6 skin 0/6 at day 12
AKR SC=>C3H AKR skin CP Persistent 9/10, day 120 Eto et al. (1990)
AKR SC=>C3H B10.BR skin 0/5 at day 13
B10.BR SC=>C3H B10.BR skin 10/10 at day 120
B10.BR SC=>C3H AKR skin 0/5 at day 14
DBA/2=>BALB/c DBA/2 skin 8/10 at day 80
DBA/2=>BALB B10.D2 skin 0/5 at day 13
DBA/2
SC=>BALB/c wt
DBA/2 skin CP Persistent 6/6 at day 100 Iwai et al. (2006)
DBA/2 SC=>Vα14
NKT KO
0/6 at day 50
B10.A=>B6 B10.A skin αCD4(d) and
αCD8(d), CP, TI,
TBI
Persistent 6/6 at day 100 Mapara et al. (2001)
aα, antibody to; BUS, busulfan; CP, cyclophosphamide; nd, non-depleting; SC, CD34+ stem cells; TBI, total body irradiation; TI, thymic irradiation; Treg, CD4+CD25+
regulatory T cells.
bN/D, not detected.
and a combined bone-marrow/renal allograft. All developed a
transient multi-lineage chimerism. Whereas one patient lost the
allograft by acute humoral rejection 10 days post transplanta-
tion, four out of the ﬁve patients, treated with a combination
of immunosuppressive drugs for up to 14months, maintained
renal function for up to 1400 days thereafter. Renal biopsies
showed normal tissue for three of these patients, with some
minor signs of chronic rejection for the fourth. In vitro studies
suggested speciﬁc absence of T cell-responses to directly pre-
sented alloantigens. However, two out of the four patients later
developed alloantibodies, one showing complement depositions
in the graft (Porcheray et al., 2009). It needs to be empha-
sized that T cell reactivity to indirectly presented donor antigens
is required for alloantibody-production by host B-lymphocytes.
The apparent absence of T cell response to directly presented
alloantigens and the production of alloantibodies are therefore
not in contradiction. Combined, these studies suggested that
long-term acceptance of (though not genuine immunological
tolerance to) kidney allografts can be obtained by a therapy
including induction of transient hematopoietic chimerism and
therefore represented a major step forward in transplantation
medicine.
Less promising results were obtained in a study in which HLA-
mismatchedpancreatic isletswere transplanted into type I diabetes
patients (Mineo et al., 2008). The conditioning regimen used
was very mild but nevertheless led to transient hematopoietic
chimerism. However, all four patients that initially adhered to
immunosuppressive therapy lost graft-function rapidly after drug
weaning.
A ROLE FOR REGULATORY T CELLS IN HEMATOPOIETIC
CHIMERISM-ASSOCIATED TOLERANCE?
At this point, one might wonder if more work is warranted to
obtain tolerance to (and therefore permanent acceptance of) organ
allografts. When considering the very promising results obtained
with kidney allografts in humans, one has to keep in mind that this
organ might represent a special case. The human islet study failed,
and the monkey and swine studies gave substantially less satisfying
results with skin and heart allografts than with renal transplants.
Moreover, in miniature swine it was shown that kidney allografts
induced tolerance to heart allografts (Madsen et al., 1998). The
thymus and Treg may play a role in this phenomenon (Yamada
et al., 1999; Mezrich et al., 2003a).
To induce genuine immunological tolerance to donor tissues,
hematopoietic chimerism needs to persist in the long term to con-
tinuously induce tolerance of newly developing lymphocytes in
primary lymphoid organs. Indeed, if hematopoietic chimerism is
only transient, mature allospeciﬁc lymphocytes will develop and,
in the absence of dominant tolerance mechanisms, will eventu-
ally destroy the graft. Long-term hematopoietic chimerism has
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Table 2 | Combined bone-marrow and organ transplantation in large animals and non-human primates.
Species Organ Conditioninga Immuno-
suppression
Hematopoietic
chimerismc
Allograft
survivald
Reference
“Cattle” Skin Co-twins None Persistent 30% at 2 years Stone et al. (1971)
Body
skin
Co-twins None Persistent 0/10 at day 68 Emery and McCul-
lagh (1980)
Auricular
skin
5/12>day 60
Dog Heart TLI, donor BM ±ATG, ±MTX,
±CsA
N/A 0/29 at day 329 Strober et al. (1984)
Kidney ALS, donor BM None N/A >14b, >17b, >38b, >78b
d,≤4/24
Caridis et al. (1973)
Kidney ALS, donor BM None N/A 0/13 at day 300 Hartner et al. (1986)
Miniature
swine
Kidney Lethal TBI±CP None Persistent >200, >200, >200, >200,
75
Guzzetta et al. (1991)
Skin αCD3-DT; TBI; TI; donor
BM
30days CsA Persistent 45, 50, >50, >235days Huang et al. (2000)
Skin αCD3-DT; TI; donor
PBSC
30days CsA Persistent >300, 45 days Fuchimoto et al.
(2000)
Kidney >120, >180, >100days,
“long term”
Fuchimoto et al.
(2000, 2001)
Rhesus
monkey
Kidney ATG, donor BM None N/A 20% at day 240 Thomas et al. (1983,
1987)
Cynomolgus
monkey
Kidney ATG; TBI; TI;
splenectomy; donor BM
4weeks CsA Transient >3478, >2569, >834e,
>771e, >405e, 260,
>198e, >196e, >137e, 72,
44, 40, 37, 40, 37 days
Kawai et al. (1995),
Kimikawa et al.
(1997b), Kawai et al.
(2002, 2004)
N/D 14, 175days
Heart Transient 509, 428, 138 days
N/D 56, 43days
Kidney ATG; TBI; TI; donor BM 4weeks CsA Transient 117, 95, 43
Kidney ATG; TBI; TI; donor BM;
aCD154
4weeks CsA Transient >1710, >1167, 755, 206,
837, 401, 373, 58
Kawai et al. (2004)
aα, antibody to; αCD3-DT, anti-CD3 antibody coupled to diphtheria toxin; ALS, anti-lymphocyte serum; ATG, antithymocyte globulin; BM, bone marrow; CP, cyclophos-
phamide; PBSC, peripheral blood stem cells; TBI, total body irradiation; TI, thymic irradiation; TLI, total lymphoid irradiation.
bRenal allografts that were not rejected but were lost for other reasons.
cN/A, not analyzed; N/D, not detected.
dAnimals that rejected their allografts are indicated in bold.
eRenal allografts that were not rejected but were lost for other reasons.
been achieved with very aggressive conditioning regimens induc-
ing total host T cell depletion. However, the level of toxicity and
the severe immunosuppression associated with this type of treat-
ment do not allow their use in the clinic. Alternative conditioning
regimens have been envisaged to avoid rejection of donor bone
marrow while allowing for survival of part of the host T cells. They
included the injection of non-depleting antibodies to block T cell
co-stimulatory pathways and the injection of antibodies speciﬁc
for some T cell markers upregulated upon activation. As described
throughout this review, these methods gave very promising results
in rodents. However, induction of a permanent chimerism was
far more difﬁcult to achieve in large animals. This observation
might be largely responsible for the less satisfying results obtained
with heart and skin allograft in miniature swine and primates.
Moreover, antibody-based therapies can also generate unpredicted
side effects that complicate translation into the clinic. For exam-
ple, the use of anti-CD154 antibody in a non-human primate
renal allograft model led to severe thromboembolic complications
(Kawai et al., 2000; Koyama et al., 2004) due to CD154 expres-
sion on activated platelets and to CD40 expression on the vascular
endothelium (Henn et al., 1998; Slupsky et al., 1998). The use
of anti-CD154 has also been associated with impaired humoral
immunity against inﬂuenza in a heart allograft model (Crowe
et al., 2003). Antibodies targeting other T cell surface markers also
present limitations as targetedmolecules can be expressed by other
populations, e.g., CD25 on Treg. While inhibiting the allogeneic
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Table 3 | Combined bone-marrow and organ transplantation in humans.
Organ Conditioninga Immuno-
suppressiona
Hematopoietic
chimerismc
Allograft
survivalb
Reference
Kidney
(HLA-matched)
ALG; CP Maintenance CsA;
azathioprine; prednisone
N/A 13/54 rejected Barber et al. (1991)
ALG; CP; donor BM 3/57 rejected
Kidney Donor BM 2weeks
ALG+maintenance
Persistent
microchimerism
21/23 at 1 year (but
“chronic rejection”)
McDaniel et al. (1994)
Transient/ND 1/7 at 1 year
Kidney
(haplocompatible)
TBI, ARA-C, CP, ATG
(splenectomy)
10months CsA, Pred Persistent >15months Sorof et al. (1995)
Kidney (related
donors)
Not speciﬁed, prior BM
transplantation to treat
hematological disorders
None Persistent >15, >30, >3months Butcher et al. (1999)
Kidney
(HLA-matched)
CP; ATG; TI; donor BM 2months CsA Transient/persistent >7.3, >5.3, >4.3, >3.5,
>2.8, >2 years
Spitzer et al. (1999),
Buhler et al. (2002),
Fudaba et al. (2006)
Kidney
(HLA-matched)
ATG; TLI; donor PBSC 6months CsA Persistent >34months Scandling et al. (2008)
Kidney
(HLA-mismatched)
CP; αCD2; TI; donor BM ≤14months CsA/Rapa Transient >1932, >1666, 10days,
>1050, >707days;
donor-speciﬁc antibodies
Kawai et al. (2008),
Porcheray et al. (2009)
Pancreatic islet
(HLA-mismatched)
High dose HSC 1 year “Edmonton”
(FK506, Rapa)
Transient 451, 480, 178, 471, 158,
510days
Mineo et al. (2008)
Liver ATG; CP; donor HSC 28–90 days FK506, Rapa Transient/ND >240, >290 Donckier et al. (2004)
aα, antibody to; ALG, anti-lymphocyte globulin; ARA-C, arabinofuranosyl cytidine; ATG, antithymocyte globulin; BM, bone marrow; CsA, cyclosporin A; CP, cyclophos-
phamide; HSC, CD34+ hematopoietic stem cells; PBSC, peripheral blood stem cells; Pred, prednisone; Rapa, Rapamycin; TBI, total body irradiation; TI, thymic
irradiation; TLI, total lymphoid irradiation.
bPatients that rejected their allografts are indicated in bold.
cN/A, not analyzed; N/D, not detected.
response, such approaches could therefore prevent the establish-
ment of regulatory mechanisms important for graft survival. They
also non-speciﬁcally inhibit T cell-dependent immunity, includ-
ing protective responses against pathogens. Finally, most of the
protocols used in large animals or currently tested in the clinic
require strong initial immunosuppressive treatments that induce
major qualitative and quantitative modiﬁcations of the immune
system that last for years. In conclusion, while highly promising,
these strategies still need to be optimized before going into the
clinic.
To overcome the issues listed above, several laboratories
embarked on studies to evaluate the potential of Treg to pro-
mote allograft protection (reviewed by Li and Turka, 2010).
The capacity of naturally occurring Treg to control allogeneic
responses was already highlighted by Sakaguchi et al. (1995)
landmark paper. Using in vivo activated polyclonal Treg with
irrelevant speciﬁcity, Karim et al. (2005) ﬁrst induced tol-
erance to allogeneic skin graft in lymphopenic Rag-deﬁcient
hosts reconstituted with naïve CD45RBhigh CD4+T cells (Karim
et al., 2005). Similar results were obtained in another lym-
phopenic system with in vitro expanded donor-speciﬁc Treg
(Golshayan et al., 2007). Interestingly, this approach also sig-
niﬁcantly prolonged skin allograft survival in unmanipulated
wild-type hosts. In a transplantation-model across minor his-
tocompatibility antigens, another group protected male skin
graft from rejection by syngeneic female hosts using Foxp3-
transduced male antigen-speciﬁc TCR transgenic CD4+ T cells
(Chai et al., 2005). In another study, a genetically manipulated
Treg population with direct and indirect alloantigen-speciﬁcity
substantially prolonged skin allograft survival and delayed chronic
rejection of heart allografts when co-injected with anti-CD8
antibody (Tsang et al., 2008). More recently, prevention of
transplant arteriosclerosis and long-term survival of skin allo-
graft were achieved with in vitro expanded naturally occurring
CD127lowCD25+CD4+ human Treg in a chimeric humanized
mouse system (Issa and Wood, 2010; Nadig et al., 2010). Com-
bined, these reports demonstrated the capacity of Treg to delay
rejection processes.
Based on the large body of literature on transplantation toler-
ance through hematopoietic chimerism and on the immunosup-
pressive potential of Treg, several laboratories decided to combine
Treg infusion with bone-marrow transplantation (Figure 1). This
method is expected to allow the establishment of complementary
tolerance mechanisms, thus mimicking the complex network of
checkpoints and regulatory systems naturally involved in mainte-
nance of self-tolerance (Figure 2). Moreover, in addition to their
generalmodulatory effects on the reactivity of the immune system,
Treg expressing the transcription factor Foxp3 have the capacity to
establish an immune-privileged niche for allogeneic hematopoi-
etic stem cells after transplantation into non-irradiated recipients
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FIGURE 1 | A regulatoryT cell/hematopoietic chimerism-based
protocol for induction of transplantation tolerance. (1) The allograft
(e.g., heart) will be transplanted with concomitant infusion of donor
BM or HSC into conditioned hosts. Rejection of the grafts will temporarily be
prevented using an immunosuppressive regimen. (2) Donor (a) and host (b)
BM will be cultured in vitro under conditions allowing for differentiation of DC.
Host DC will be pulsed with donor antigen to assure indirect presentation of
these antigens. Thus generated DC will then be co-cultured with host-derived
Treg (c), allowing for expansion of Treg speciﬁc for directly and indirectly
presented donor antigens. (3) Thus generated donor-antigen-speciﬁc Treg will
then be infused into the host. Immunosuppression may temporarily be
continued using drugs that do not affect Treg (e.g., Rapamycin). Using this
protocol, full tolerance to donor-tissue will be achieved and chronic rejection
effectively prevented.
(Fujisaki et al., 2011). The co-injection of Treg with allogeneic
bone-marrow should therefore promote its engraftment.Adminis-
tration of donor-speciﬁcTreg prevented rejection of bone-marrow
allografts in preconditioned mice (Joffre et al., 2004; Joffre and
van Meerwijk, 2006). Promising results were later obtained using
polyclonal donor Treg (Hanash and Levy, 2005). However, similar
protocols failed to substantially prolong survival of skin and heart
allografts (Joffre et al., 2008; Tsang et al., 2008; Pilat et al., 2010).
In contrast, when combined with bone-marrow transplantation,
administration of a single dose of Treg fully prevented rejection
of skin and heart (Joffre et al., 2008). Whereas Treg speciﬁc for
directly presented donor-antigens allowed for survival of bone-
marrow allografts, they failed to prevent chronic rejection of skin
and heart. In contrast, Treg speciﬁc for indirectly presented donor-
antigens fully prevented chronic heart and skin allograft rejection
(Joffre et al., 2008). These results ﬁrmly demonstrated the clinical
potential of Treg infusion in inductionof bone-marrowchimerism
and in the subsequent prevention of acute and chronic allograft
rejection.
TREG AND HEMATOPOIETIC CHIMERISM-BASED
STRATEGIES: SOME LIMITATIONS TO OVERCOME
The data described above constitute a proof of principle that com-
bining Treg and bone-marrow infusion can lead to subsequent
tolerance to allogeneic tissues, even in very stringent donor/host
combinations and for highly immunogenic tissues such as the
skin. However, 5 Gy total body irradiation was required in that
protocol (Joffre et al., 2008). This dose appears not suitable for
clinical use as it is associated with severe temporary leukopenia.
Interestingly, the groupofWekerle recently induced hematopoietic
chimerism in mice using a comparable approach, but without or
with very limited cytoreductive conditioning (Pilat et al., 2010,
2011). Treatment with costimulation-blocking agents, a short
course of rapamycin, and injection of polyclonal Treg allowed for
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FIGURE 2 |Tolerance mechanisms induced by the proposed
regulatoryT cell/hematopoietic chimerism-based protocol for
induction of transplantation tolerance. (1) Hematopoietic cells
(e.g., DC) derived from the grafted BM will colonize the recipient’s
thymus and induce deletion and anergy (i.e., “recessive tolerance”) of
developing donor-speciﬁc host T lymphocytes. DC may also promote
limited differentiation of donor-speciﬁc Treg that will contribute to
transplantation tolerance. (2) Donor DC will also induce recessive
tolerance of mature peripheral donor-speciﬁc T lymphocytes. These
cells may, to a limited extent, directly induce donor-speciﬁc Treg.
However, the dominant tolerance (i.e., Treg) induce by hematopoietic
chimerism in (1) and (2) appears insufﬁcient to durably prevent most notably
chronic allograft rejection. (3) Infusion of donor-speciﬁc Treg will aid in
engraftment of grafted donor BM/HSC (a) and inhibit the reactivity of mature
peripheral donor-speciﬁc T lymphocytes (b), thus favoring graft-acceptance.
They will also allow the differentiation of donor-speciﬁc conventional T
lymphocytes into Treg (c), thus assuring persistence of tolerance and
preventing chronic allograft rejection.
induction of hematopoietic chimerism. Skin grafts transplanted
on these mice survived for more than 160 days, without signs of
rejection or appearance of donor-speciﬁc antibodies (Pilat et al.,
2010). More recently, this group raised similar conclusions using
polyclonal host CD4+ lymphocytes previously transduced with
a retroviral vector containing Foxp3 and a drug-free condition-
ing regimen where 1Gy total body irradiation replaced the short
course of rapamycin (Pilat et al., 2011). These protocols repre-
sent a major step forward to the clinic. However, they still rely on
anti-CD154 treatment and this antibody is presently not usable
in patients (see above). Different non-mutually exclusive strate-
gies can be envisaged to avoid co-stimulatory-blockade. The use
of hematopoietic or mesenchymal stem cells instead of bone-
marrow cells could be an option, as this will signiﬁcantly reduce
the immunogenicity of the graft. Another strategy would be to
improve the efﬁciency of the immunosuppression by injecting
donor-speciﬁc Treg. Alloantigen-speciﬁc T cells survived longer
and in several transplantation models gave substantially better
results thanpolyclonal Tregswith irrelevant speciﬁcity (Joffre et al.,
2004, 2008; Nishimura et al., 2004; Golshayan et al., 2007).
Another aspect that still needs to be tested before translat-
ing Treg-based strategies into the clinic is represented by the
antigen-speciﬁcity of the treatments. Indeed, if Treg activation is
antigen speciﬁc, these cells exert their suppressor effector function
in a non-antigen-speciﬁc-manner in vitro (Thornton and Shevach,
2000). If true in vivo, infused Treg may therefore inhibit protec-
tive immunity. However, it has been shown that hematopoietic
chimerism/Treg-based therapy against allograft rejection is (at
least) donor speciﬁc. A related issue is that tolerance to donor-
antigen may be broken by (e.g., viral) infection (Welsh et al., 2000;
Williams et al., 2001; Forman et al., 2002). It therefore also needs
to be veriﬁed to what extent Treg-based therapies are resistant to
infection. Experimental work will need to be performed to clarify
these important issues.
Finally, infused Treg do not necessarily survive indeﬁnitely and
tolerance may therefore wane away with time. In other trans-
plantation models, however, it was shown that a tolerant T cell
population can render naïve T cells tolerant and even tolerogenic
(Waldmann, 2010). Very recently it was shown that this so-called
“infectious tolerance” depends on Treg that induce novel Treg
required for persistence of tolerance to allografts (Kendal et al.,
2011). Even if it remains to be shown that also infused Treg can
cause infectious tolerance, it appears therefore that Treg can induce
life-long tolerance to allografts.
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CONCLUSION
The data discussed here indicate that induction of persistent
hematopoietic chimerism combined with infusion of Treg with
appropriate speciﬁcity efﬁciently leads to life-long tolerance to
allografts in experimental animalmodels (Figure 1). Thus, andnot
very surprisingly so, the mechanisms involved in the maintenance
of tolerance to self antigens also appear required for tolerance to
donor antigens (Figure 2). More work will need to be performed
to establish conditioning regimens compatible with clinical con-
straints and to assess immunocompetence of grafted animals. The
validity of these conclusions for non-humanprimates andhumans
remains to be studied. Very substantial progress has been made in
recent years in the inductionof authentic immunological tolerance
to allogeneic organ grafts, and transplant recipients may soon be
able to live a life free of the fear of losing the graft and of the severe
side effects of immunosuppressive drugs.
REFERENCES
Adams, A. B., Durham, M. M., Kean,
L., Shirasugi, N., Ha, J., Williams,
M. A., Rees, P. A., Cheung, M. C.,
Mittelstaedt, S., Bingaman, A. W.,
Archer, D. R., Pearson, T. C., Waller,
E. K., and Larsen, C. P. (2001).
Costimulation blockade, busulfan,
and bonemarrowpromote titratable
macrochimerism, induce transplan-
tation tolerance, and correct genetic
hemoglobinopathies with minimal
myelosuppression. J. Immunol. 167,
1103–1111.
Alard, P., Matriano, J. A., Socarras, S.,
Ortega, M.-A., and Streilein, J. W.
(1995). Detection of donor-derived
cells by polymerase chain reaction in
neonatally tolerant mice. Transplan-
tation 60, 1125–1130.
Anderson, G., Partington, K. M., and
Jenkinson, E. J. (1998). Differential
effects of peptide diversity and stro-
mal cell type in positive and negative
selection in the thymus. J. Immunol.
161, 6599–6603.
Aschenbrenner, K., D’Cruz, L. M., Voll-
mann, E. H., Hinterberger, M.,
Emmerich, J., Swee, L. K., Rolink,
A., and Klein, L. (2007). Selection of
Foxp3(+) regulatory T cells speciﬁc
for self antigen expressed and pre-
sented by Aire(+) medullary thymic
epithelial cells. Nat. Immunol. 8,
351–358.
Baba, T., Nakamoto, Y., and Mukaida,
N. (2009). Crucial contribution of
thymic Sirp alpha+ conventional
dendritic cells to central toler-
ance against blood-borne antigens
in a CCR2-dependent manner. J.
Immunol. 183, 3053–3063.
Barber, W. H., Mankin, J. A., Laskow,
D. A., Deierhoi, M. H., Julian, B.
A., Curtis, J. J., and Diethelm, A.
G. (1991). Long-term results of a
controlled prospective study with
transfusion of donor-speciﬁc bone
marrow in 57 cadaveric renal allo-
graft recipients. Transplantation 51,
70–75.
Bensinger, S. J., Bandeira, A., Jordan,
M. S., Caton, A. J., and Laufer, T.
M. (2001). Major histocompatibil-
ity complex class II-positive corti-
cal epithelium mediates the selec-
tion of CD4+25+ immunoregu-
latory T cells. J. Exp. Med. 194,
427–438.
Bigenzahn, S., Blaha, P., Koporc, Z.,
Pree, I., Selzer, E., Bergmeister, H.,
Wrba, F., Heusser, C., Wagner, K.,
Muehlbacher, F., and Wekerle, T.
(2005). The role of non-deletional
tolerance mechanisms in a murine
model of mixed chimerismwith cos-
timulation blockade. Am. J. Trans-
plant. 5, 1237–1247.
Billingham, R. E., Brent, L., and
Medawar, P. B. (1953). Actively
acquired tolerance of foreign cells.
Nature 172, 603–606.
Billingham, R. E., Lampkin, G. H.,
Medawar, P. B., and Williams, H. L.
L. (1952). Tolerance to homografts,
twin diagnosis, and the freemartin
condition in cattle. Heredity 6,
201–212.
Blom, D., Morrissey, N. J., Mesonero,
C., Coppage, M., Fisher, T., Zuo, X.
J., Jordan, S. C., and Orloff, M. S.
(1996). Induction of speciﬁc toler-
ance through mixed hematopoietic
chimerism prevents chronic renal
allograft rejection in a rat model.
Surgery 120, 213–219; discussion
219–220.
Boise, L. H.,Minn,A. J., Noel, P. J., June,
C. H., Accavitti, M. A., Lindsten, T.,
and Thompson, C. B. (1995). CD28
costimulation can promote T cell
survival by enhancing the expression
of Bcl-XL. Immunity 3, 87–98.
Bonasio, R., Scimone, M. L., Schaerli,
P., Grabie, N., Lichtman, A. H., and
von Andrian, U. H. (2006). Clonal
deletion of thymocytes by circulat-
ing dendritic cells homing to the thy-
mus. Nat. Immunol. 7, 1092–1100.
Boyse, E. A., Carswell, E. A., Scheid, M.
P., and Old, L. J. (1973). Tolerance of
Sk-incompatible skin grafts. Nature
244, 441–442.
Boyse, E. A., Lance, E. M., Carswell, E.
A., Cooper, S., and Old, L. J. (1970).
Rejection of skin allografts by radia-
tion chimaeras: selective gene action
in the speciﬁcation of cell surface
structure. Nature 227, 901–903.
Brocades Zaalberg, A., Vos, O., and
Bekkum Van, D. W. (1957). Surviv-
ing rat skin grafts in mice. Nature
180, 238–239.
Brocker, T., Riedinger, M., and Kar-
jalainen, K. (1997). Targeted expres-
sion of major histocompatibility
complex (MHC) class II molecules
demonstrates that dendritic cells can
induce negative but not positive
selection of thymocytes in vivo. J.
Exp. Med. 185, 541–550.
Buhler, L. H., Spitzer, T. R., Sykes,
M., Sachs, D. H., Delmonico, F.
L., Tolkoff-Rubin, N., Saidman, S.
L., Sackstein, R., McAfee, S., Dey,
B., Colby, C., and Cosimi, A. B.
(2002). Induction of kidney allograft
tolerance after transient lymphohe-
matopoietic chimerism in patients
with multiple myeloma and end-
stage renal disease. Transplantation
74, 1405–1409.
Butcher, J. A., Hariharan, S., Adams, M.
B., Johnson, C. P., Roza, A. M., and
Cohen,E. P. (1999). Renal transplan-
tation for end-stage renal disease
following bone marrow transplanta-
tion: a report of six cases, with and
without immunosuppression. Clin.
Transplant. 13, 330–335.
Caridis, D. T., Liegeois, A., Barrett, I.,
and Monaco, A. P. (1973). Enhanced
survival of canine renal allografts of
ALS- treated dogs given bone mar-
row. Transplant. Proc. 5, 671–674.
Chai, J. G., Xue, S. A., Coe, D.,
Addey, C., Bartok, I., Scott, D.,
Simpson, E., Stauss, H. J., Hori,
S., Sakaguchi, S., and Dyson, J.
(2005). Regulatory T cells, derived
from naive CD4+CD25- T cells by
in vitro Foxp3 gene transfer, can
induce transplantation tolerance.
Transplantation 79, 1310–1316.
Colson, Y. L., Wren, S. M., Schuchert,
M. J., Patrene, K. D., John-
son, P. C., Boggs, S. S., and
Ildstad, S. T. (1995a). A non-
lethal conditioning approach to
achieve durable multilineage mixed
chimerism and tolerance across
major, minor, and hematopoi-
etic histocompatibility barriers. J.
Immunol. 155, 4179–4188.
Colson, Y. L., Zadach, K., Nalesnik, M.,
and Ildstad, S. T. (1995b). Mixed
allogeneic chimerism in the rat.
Donor-speciﬁc transplantation tol-
erance without chronic rejection for
primarily vascularized cardiac allo-
grafts. Transplantation 60, 971–980.
Cosimi, A. B., and Sachs, D. H. (2004).
Mixed chimerism and transplanta-
tion tolerance. Transplantation 77,
943–946.
Crowe, J. E. Jr., Sannella, E. C., Pfeif-
fer, S., Zorn, G. L., Azimzadeh, A.,
Newman, R., Miller, G. G., and
Pierson, R. N. (2003). CD154 reg-
ulates primate humoral immunity
to inﬂuenza. Am. J. Transplant. 3,
680–688.
Domenig, C., Sanchez-Fueyo, A., Kurtz,
J., Alexopoulos, S. P., Mariat, C.,
Sykes,M.,Strom,T. B., andZheng,X.
X. (2005). Roles of deletion and reg-
ulation in creating mixed chimerism
and allograft tolerance using a
nonlymphoablative irradiation-
free protocol. J. Immunol. 175,
51–60.
Donckier, V., Troisi, R., Toungouz, M.,
Colle, I.,VanVlierberghe,H., Jacquy,
C., Martiat, P., Stordeur, P., Zhou, L.,
Boon, N., Lambermont, M., Schan-
dene, L., Van Laethem, J. L., Noens,
L., Gelin, M., de Hemptinne, B., and
Goldman, M. (2004). Donor stem
cell infusion after non-myeloablative
conditioning for tolerance induction
to HLA mismatched adult living-
donor liver graft. Transpl. Immunol.
13, 139–146.
Donckier, V., Wissing, M., Bruyns, C.,
Abramowicz, D., Lybin, M., Van-
derhaeghen, M. L., and Goldman,
M. (1995). Critical role of inter-
leukin 4 in the induction of neona-
tal transplantation tolerance. Trans-
plantation 59, 1571–1576.
Emery, D., and McCullagh, P. (1980).
Immunological reactivity between
chimeric cattle twins. I. Homograft
reaction. Transplantation 29, 4–9.
Eto, M., Mayumi, H., Tomita, Y.,
Yoshikai, Y., and Nomoto, K.
(1990). Intrathymic clonal dele-
tion of V beta 6+ T cells
in cyclophosphamide-induced tol-
erance to H-2-compatible, Mls-
disparate antigens. J. Exp. Med. 171,
97–113.
Fehr, T., Haspot, F., Mollov, J., Chit-
tenden, M., Hogan, T., and Sykes,
M. (2008a). Alloreactive CD8 T cell
tolerance requires recipient B cells,
dendritic cells, and MHC class II. J.
Immunol. 181, 165–173.
Fehr, T., Wang, S., Haspot, F., Kurtz, J.,
Blaha, P., Hogan, T., Chittenden, M.,
Wekerle, T., and Sykes, M. (2008b).
Rapid deletional peripheral CD8 T
cell tolerance induced by allogeneic
bone marrow: role of donor class II
MHC and B cells. J. Immunol. 181,
4371–4380.
www.frontiersin.org December 2011 | Volume 2 | Article 80 | 11
Pasquet et al. Hematopoietic chimerism, Treg, and transplantation tolerance
Fontenot, J. D., and Rudensky, A. Y.
(2005). A well adapted regulatory
contrivance: regulatory T cell devel-
opment and the forkhead fam-
ily transcription factor Foxp3. Nat.
Immunol. 6, 331–337.
Forman, D., Welsh, R. M., Markees, T.
G.,Woda,B.A.,Mordes, J. P.,Rossini,
A. A., and Greiner,D. L. (2002).Viral
abrogation of stem cell transplanta-
tion tolerance causes graft rejection
and host death by different mecha-
nisms. J. Immunol. 168, 6047–6056.
Fuchimoto,Y.,Huang,C.A.,Yamada,K.,
Gleit, Z. L., Kitamura,H.,Griesemer,
A., Scheier-Dolberg, R., Melendy, E.,
White-Scharf,M. E., and Sachs,D.H.
(2001). Induction of kidney allograft
tolerance through mixed chimerism
in miniature swine. Transplant. Proc.
33, 77.
Fuchimoto,Y.,Huang,C.A.,Yamada,K.,
Shimizu,A.,Kitamura,H.,Colvin,R.
B., Ferrara,V., Murphy, M. C., Sykes,
M., White-Scharf, M., Neville, D. M.
Jr., and Sachs, D. H. (2000). Mixed
chimerism and tolerance without
whole body irradiation in a large
animal model. J. Clin. Invest. 105,
1779–1789.
Fudaba, Y., Spitzer, T. R., Shaffer, J.,
Kawai, T., Fehr, T., Delmonico, F.,
Preffer, F., Tolkoff-Rubin, N., Dey, B.
R., Saidman, S. L., Kraus, A., Bon-
nefoix, T., McAfee, S., Power, K.,
Kattleman, K., Colvin, R. B., Sachs,
D. H., Cosimi, A. B., and Sykes,
M. (2006). Myeloma responses and
tolerance following combined kid-
ney and nonmyeloablative mar-
row transplantation: in vivo and
in vitro analyses. Am. J. Transplant.
6, 2121–2133.
Fujisaki, J., Wu, J., Carlson, A. L., Sil-
berstein, L., Putheti, P., Larocca,
R., Gao, W., Saito, T. I., Lo
Celso, C., Tsuyuzaki, H., Sato, T.,
Cote, D., Sykes, M., Strom, T. B.,
Scadden, D. T., and Lin, C. P.
(2011). In vivo imaging of Treg
cells providing immune privilege to
the haematopoietic stem-cell niche.
Nature 474, 216–219.
Golshayan, D., Jiang, S., Tsang, J., Garin,
M. I., Mottet, C., and Lechler, R.
I. (2007). In vitro-expanded donor
alloantigen-speciﬁc CD4+CD25+
regulatory T cells promote exper-
imental transplantation tolerance.
Blood 109, 827–835.
Guo, Z., Wang, J., Dong, Y., Adams,
A. B., Shirasugi, N., Kim, O., Hart,
J., Newton-West, M., Pearson, T.
C., Larsen, C. P., and Newell, K.
A. (2003). Long-term survival of
intestinal allografts induced by cos-
timulation blockade, busulfan and
donor bone marrow infusion. Am.
J. Transplant. 3, 1091–1098.
Guzzetta, P. C., Sundt, T. M., Suzuki,
T., Mixon, A., Rosengard, B. R.,
and Sachs, D. H. (1991). Induc-
tion of kidney transplantation tol-
erance across major histocompat-
ibility complex barriers by bone
marrow transplantation in minia-
ture swine. Transplantation 51,
862–866.
Hanash, A. M., and Levy, R. B.
(2005). Donor CD4+CD25+ T cells
promote engraftment and toler-
ance following MHC-mismatched
hematopoietic cell transplantation.
Blood 105, 1828–1836.
Hartner, W. C., De Fazio, S. R.,
Maki, T., Markees, T. G., Monaco,
A. P., and Gozzo, J. J. (1986).
Prolongation of renal allograft
survival in antilymphocyte-serum-
treated dogs by postoperative
injection of density-gradient-
fractionated donor bone marrow.
Transplantation 42, 593–597.
Hawiger, D., Inaba, K., Dorsett, Y., Guo,
M., Mahnke, K., Rivera, M., Ravetch,
J. V., Steinman, R. M., and Nussen-
zweig, M. C. (2001). Dendritic cells
induce peripheral T cell unrespon-
siveness under steady state condi-
tions in vivo. J. Exp. Med. 194,
769–779.
Henn,V., Slupsky, J. R., Grafe,M.,Anag-
nostopoulos, I., Forster, R., Muller-
Berghaus, G., and Kroczek, R. A.
(1998). CD40 ligand on activated
platelets triggers an inﬂammatory
reaction of endothelial cells. Nature
391, 591–594.
Hogquist, K. A., Baldwin, T. A., and
Jameson, S. C. (2005). Central toler-
ance: learning self-control in the thy-
mus. Nat. Rev. Immunol. 5, 772–782.
Horner, B. M., Cina, R. A., Wikiel,
K. J., Lima, B., Ghazi, A., Lo, D.
P., Yamada, K., Sachs, D. H., and
Huang, C. A. (2006). Predictors of
organ allograft tolerance following
hematopoietic cell transplantation.
Am. J. Transplant. 6, 2894–2902.
Hsieh, C. S., Liang, Y., Tyznik, A. J., Self,
S. G., Liggitt, D., and Rudensky, A. Y.
(2004). Recognition of the periph-
eral self by naturally arising CD25+
CD4+Tcell receptors. Immunity 21,
267–277.
Huang, C. A., Fuchimoto, Y., Scheier-
Dolberg, R., Murphy, M. C., Neville,
D. M. Jr., and Sachs, D. H. (2000).
Stable mixed chimerism and tol-
erance using a nonmyeloablative
preparative regimen in a large-
animal model. J. Clin. Invest. 105,
173–181.
Hudrisier, D., Feau, S., Bonnet, V.,
Romagnoli, P., and van Meer-
wijk, J. P. M. (2003). In vivo
unresponsiveness of T lympho-
cyte induced by thymic medullary
epithelium requires antigen pre-
sentation by radioresistant cells.
Immunology 108, 24–31.
Ildstad, S. T., and Sachs, D. H. (1984).
Reconstitution with syngeneic plus
allogeneic or xenogeneic bone mar-
row leads to speciﬁc acceptance of
allografts or xenografts. Nature 307,
168–170.
Issa, F., and Wood, K. J. (2010). CD4+
regulatory T cells in solid organ
transplantation. Curr. Opin. Organ.
Transplant.
Iwai, T., Tomita, Y., Okano, S., Shimizu,
I., Yasunami, Y., Kajiwara, T.,
Yoshikai, Y., Taniguchi, M., Nomoto,
K., and Yasui, H. (2006). Reg-
ulatory roles of NKT cells in
the induction and maintenance
of cyclophosphamide-induced toler-
ance. J. Immunol. 177, 8400–8409.
Jenkinson, E. J., Anderson, G., and
Owen, J. J. (1992). Studies on T cell
maturation on deﬁned thymic stro-
mal cell populations in vitro. J. Exp.
Med. 176, 845–853.
Joffre, O., Gorsse, N., Romagnoli, P.,
Hudrisier, D., and van Meerwijk, J.
P. M. (2004). Induction of antigen-
speciﬁc tolerance to bone marrow
allograftswithCD4+CD25+T lym-
phocytes. Blood 103, 4216–4221.
Joffre, O., Santolaria, T., Calise, D.,
Al Saati, T., Hudrisier, D., Romag-
noli, P., and van Meerwijk, J. P.
M. (2008). Prevention of acute
and chronic allograft rejection with
CD4+CD25+Foxp3+ regulatory T
lymphocytes. Nat. Med. 14, 88–92.
Joffre, O., and van Meerwijk, J. P.
M. (2006). CD4+CD25+ regula-
tory T lymphocytes in bone marrow
transplantation. Semin. Immunol.
18, 128–135.
Ju, S. T.,Panka,D. J.,Cui,H.,Ettinger,R.,
el-Khatib, M., Sherr, D. H., Stanger,
B. Z., and Marshak-Rothstein, A.
(1995). Fas(CD95)/FasL interac-
tions required for programmed cell
death after T-cell activation. Nature
373, 444–448.
Kahan, B. D. (2003). Individuality:
the barrier to optimal immuno-
suppression. Nat. Rev. Immunol. 3,
831–838.
Kappler, J. W., Roehm,N., and Marrack,
P. (1987a). T cell tolerance by clonal
elimination in the thymus. Cell 49,
273–280.
Kappler, J. W.,Wade, T.,White, J., Kush-
nir, E., Blackman,M., Bill, J., Roehm,
N., and Marrack, P. (1987b). A T cell
receptorVbeta segment that imparts
reactivity to a class II major histo-
compatibility complex product. Cell
49, 263–271.
Kappler, J. W., Staerz, U., White, J.,
and Marrack, P. C. (1988). Self-
tolerance eliminates T cells speciﬁc
for Mls-modiﬁed products of the
major histocompatibility complex.
Nature 332, 35–40.
Karim, M., Feng, G., Wood, K. J., and
Bushell, A. R. (2005). CD25+CD4+
regulatory T cells generated by expo-
sure to a model protein antigen
prevent allograft rejection: antigen-
speciﬁc reactivation in vivo is critical
for bystander regulation. Blood 105,
4871–4877.
Kawai, T., Andrews, D., Colvin, R. B.,
Sachs, D. H., and Cosimi, A. B.
(2000). Thromboembolic complica-
tions after treatment with mono-
clonal antibody against CD40 lig-
and. Nat. Med. 6, 114.
Kawai, T., Cosimi, A. B., Colvin, R. B.,
Powelson, J., Eason, J., Kozlowski,
T., Sykes, M., Monroy, R., Tanaka,
M., and Sachs, D. H. (1995).
Mixed allogeneic chimerism and
renal allograft tolerance in cynomol-
gus monkeys. Transplantation 59,
256–262.
Kawai, T., Cosimi, A. B., Spitzer, T.
R., Tolkoff-Rubin, N., Suthanthi-
ran, M., Saidman, S. L., Shaffer, J.,
Preffer, F. I., Ding, R., Sharma, V.,
Fishman, J. A., Dey, B., Ko, D. S.,
Hertl, M., Goes, N. B., Wong, W.,
Williams, W. W. Jr., Colvin, R. B.,
Sykes, M., and Sachs, D. H. (2008).
HLA-mismatched renal transplanta-
tion without maintenance immuno-
suppression. N. Engl. J. Med. 358,
353–361.
Kawai, T., Cosimi, A. B., Wee, S. L.,
Houser, S., Andrews, D., Sogawa, H.,
Phelan, J., Boskovic, S., Nadazdin,
O., Abrahamian, G., Colvin, R.
B., Sachs, D. H., and Madsen,
J. C. (2002). Effect of mixed
hematopoietic chimerism on car-
diac allograft survival in cynomol-
gus monkeys. Transplantation 73,
1757–1764.
Kawai, T., Poncelet, A., Sachs, D. H.,
Mauiyyedi, S., Boskovic, S., Wee,
S. L., Ko, D. S., Bartholomew, A.,
Kimikawa, M., Hong, H. Z., Abra-
hamian, G., Colvin, R. B., and
Cosimi, A. B. (1999). Long-term
outcome and alloantibody produc-
tion in a non-myeloablative regi-
men for induction of renal allo-
graft tolerance. Transplantation 68,
1767–1775.
Kawai, T., Sogawa, H., Boskovic, S.,
Abrahamian, G., Smith, R. N.,
Wee, S. L., Andrews, D., Nadazdin,
O., Koyama, I., Sykes, M., Winn,
H. J., Colvin, R. B., Sachs, D.
H., and Cosimi, A. B. (2004).
CD154 blockade for induction of
mixed chimerism and prolonged
renal allograft survival in nonhu-
man primates. Am. J. Transplant. 4,
1391–1398.
Frontiers in Immunology | Immunological Tolerance December 2011 | Volume 2 | Article 80 | 12
Pasquet et al. Hematopoietic chimerism, Treg, and transplantation tolerance
Kendal, A. R., Chen, Y., Regateiro, F. S.,
Ma, J., Adams, E., Cobbold, S. P.,
Hori, S., and Waldmann, H. (2011).
Sustained suppression by Foxp3+
regulatory T cells is vital for infec-
tious transplantation tolerance. J.
Exp. Med. 208, 2043–2053.
Khan, A., Tomita, Y., and Sykes, M.
(1996). Thymic dependence of loss
of tolerance in mixed allogeneic
bone marrow chimeras after deple-
tion of donor antigen. Peripheral
mechanisms do not contribute to
maintenance of tolerance. Trans-
plantation 62, 380–387.
Kimikawa, M., Kawai, T., Sachs, D.
H., Colvin, R. B., Bartholomew, A.,
and Cosimi, A. B. (1997a). Mixed
chimerism and transplantation tol-
erance induced by a nonlethal
preparative regimen in cynomolgus
monkeys. Transplant. Proc. 29, 1218.
Kimikawa, M., Sachs, D. H., Colvin,
R. B., Bartholomew, A., Kawai, T.,
and Cosimi, A. B. (1997b). Modi-
ﬁcations of the conditioning regi-
men for achieving mixed chimerism
and donor-speciﬁc tolerance in
cynomolgus monkeys. Transplanta-
tion 64, 709–716.
Kleindienst, P., Chretien, I., Winkler, T.,
and Brocker, T. (2000). Functional
comparison of thymic B cells and
dendritic cells in vivo. Blood 95,
2610–2616.
Koyama, I., Kawai, T., Andrews, D.,
Boskovic, S., Nadazdin, O., Wee, S.
L., Sogawa, H., Wu, D. L., Smith, R.
N., Colvin, R. B., Sachs, D. H., and
Cosimi,A. B. (2004). Thrombophilia
associated with anti-CD154 mono-
clonal antibody treatment and its
prophylaxis in nonhuman primates.
Transplantation 77, 460–462.
Kurtz, J., Shaffer, J., Lie, A., Anosova, N.,
Benichou, G., and Sykes, M. (2004).
Mechanisms of early peripheral CD4
T-cell tolerance induction by anti-
CD154 monoclonal antibody and
allogeneic bone marrow transplan-
tation: evidence for anergy and dele-
tion but not regulatory cells. Blood
103, 4336–4343.
Larsen, C. P., Elwood, E. T., Alexan-
der, D. Z., Ritchie, S. C., Hendrix,
R., Tucker-Burden, C., Cho, H. R.,
Aruffo, A., Hollenbaugh, D., Lins-
ley, P. S., Winn, K. J., and Pearson,
T. C. (1996). Long-term acceptance
of skin and cardiac allografts after
blocking CD40 and CD28 pathways.
Nature 381, 434–438.
Le Douarin,N.,Corbel,C., Bandeira,A.,
Thomas-Vaslin, V., Modigliani, Y.,
Coutinho, A., and Salaun, J. (1996).
Evidence for a thymus-dependent
form of tolerance that is not based
on elimination or anergy of reactive
T cells. Immunol. Rev. 149, 35–53.
Lenardo, M. J. (1991). Interleukin-2
programs mouse alpha beta T lym-
phocytes for apoptosis. Nature 353,
858–861.
Li, X. C., and Turka, L. A. (2010). An
update on regulatory T cells in trans-
plant tolerance and rejection. Nat.
Rev. Nephrol. 6, 577–583.
Lubaroff, D. M., and Silvers, W.
K. (1973). The importance of
chimerism in maintaining toler-
ance of skin allografts in mice. J.
Immunol. 111, 65–71.
Luo, B., Chan, W. F., Shapiro, A. M.,
and Anderson, C. C. (2007). Non-
myeloablative mixed chimerism
approaches and tolerance, a split
decision. Eur. J. Immunol. 37,
1233–1242.
Luo, B., Nanji, S. A., Schur, C. D.,
Pawlick, R. L., Anderson, C. C., and
Shapiro, A. M. (2005). Robust tol-
erance to fully allogeneic islet trans-
plants achieved by chimerism with
minimal conditioning. Transplanta-
tion 80, 370–377.
Luther, S. A., and Acha-Orbea, H.
(1997). Mouse mammary tumor
virus: immunological interplays
between virus and host. Adv.
Immunol. 65, 139–243.
MacDonald, H. R., Pedrazzini, T.,
Schneider, R., Louis, J. A., Zinker-
nagel, R. M., and Hengartner, H.
(1988a). Intrathymic elimination of
Mlsa-reactive (V beta 6+) cells dur-
ing neonatal tolerance induction to
Mlsa-encoded antigens. J. Exp. Med.
167, 2005–2010.
MacDonald, H. R., Schneider, R., Lees,
R. K., Howe, R. C., Acha-Orbea, H.,
Festenstein, H., Zinkernagel, R. M.,
and Hengartner, H. (1988b). T-cell
receptor V beta use predicts reactiv-
ity and tolerance to Mlsa-encoded
antigens. Nature 332, 40–45.
Madsen, J. C., Yamada, K., Allan, J. S.,
Choo, J. K., Erhorn, A. E., Pins,
M. R., Vesga, L., Slisz, J. K., and
Sachs, D. H. (1998). Transplantation
tolerance prevents cardiac allograft
vasculopathy in major histocom-
patibility complex class I-disparate
miniature swine.Transplantation 65,
304–313.
Main, J. M., and Prehn, R. T. (1955).
Successful skin homografts after the
administration of high dosage X
radiation and homologous bone
marrow. J. Natl. Cancer Inst. 15,
1023–1029.
Manilay, J. O., Pearson, D. A., Ser-
gio, J. J., Swenson, K. G., and
Sykes, M. (1998). Intrathymic dele-
tion of alloreactive T cells in mixed
bone marrow chimeras prepared
with a nonmyeloablative condition-
ing regimen. Transplantation 66,
96–102.
Mapara, M. Y., Pelot, M., Zhao, G.,
Swenson, K., Pearson, D., and
Sykes, M. (2001). Induction of sta-
ble long-term mixed hematopoi-
etic chimerism following nonmye-
loablative conditioning with T cell-
depleting antibodies, cyclophos-
phamide, and thymic irradiation
leads to donor-speciﬁc in vitro and
in vivo tolerance.Biol. BloodMarrow
Transplant. 7, 646–655.
Matzinger, P., and Guerder, S. (1989).
Does T-cell tolerance require a
dedicated antigen-presenting cell?
Nature 338, 74–76.
Mayumi, H., and Good, R. A. (1989).
Long-lasting skin allograft toler-
ance in adult mice induced across
fully allogeneic (multimajor H-2
plus multiminor histocompatibil-
ity) antigen barriers by a tolerance-
inducing method using cyclophos-
phamide. J. Exp. Med. 169, 213–238.
McDaniel, D. O., Naftilan, J., Hulvey,
K., Shaneyfelt, S., Lemons, J. A.,
Lagoo-Deenadayalan, S.,Hudson, S.,
Diethelm, A. G., and Barber, W. H.
(1994). Peripheral blood chimerism
in renal allograft recipients trans-
fused with donor bone marrow.
Transplantation 57, 852–856.
Meier-Kriesche, H. U., and Kaplan, B.
(2011). The search for CNI-free
immunosuppression: no free lunch.
Am. J. Transplant. 11, 1355–1356.
Metzler, B., Gfeller, P., Bigaud, M., Li,
J., Wieczorek, G., Heusser, C., Lake,
P., and Katopodis, A. (2004). Com-
binations of anti-LFA-1, everolimus,
anti-CD40 ligand, and allogeneic
bone marrow induce central trans-
plantation tolerance through hemo-
poietic chimerism, including pro-
tection from chronic heart allo-
graft rejection. J. Immunol. 173,
7025–7036.
Mezrich, J. D., Kesselheim, J. A., John-
ston, D. R., Yamada, K., Sachs, D.
H., and Madsen, J. C. (2003a). The
role of regulatory cells in miniature
swine rendered tolerant to cardiac
allografts by donor kidney cotrans-
plantation. Am. J. Transplant. 3,
1107–1115.
Mezrich, J. D., Yamada, K., Lee, R.
S., Mawulawde, K., Benjamin, L.
C., Schwarze, M. L., Maloney, M.
E., Amoah, H. C., Houser, S. L.,
Sachs, D. H., and Madsen, J. C.
(2003b). Induction of tolerance to
heart transplants by simultaneous
cotransplantation of donor kidneys
may depend on a radiation-sensitive
renal-cell population. Transplanta-
tion 76, 625–631.
Mineo, D., Ricordi, C., Xu, X., Pileggi,
A., Garcia-Morales, R., Khan, A.,
Baidal, D. A., Han, D., Monroy,
K., Miller, J., Pugliese, A., Froud,
T., Inverardi, L., Kenyon, N. S.,
and Alejandro, R. (2008). Com-
bined islet and hematopoietic stem
cell allotransplantation: a clinical
pilot trial to induce chimerism and
graft tolerance. Am. J. Transplant. 8,
1262–1274.
Monaco, A. P. (2003). Chimerism in
organ transplantation: conﬂicting
experiments and clinical observa-
tions. Transplantation 75, 13S-16S.
Nadig, S. N., Wieckiewicz, J., Wu, D.
C., Warnecke, G., Zhang, W., Luo,
S., Schiopu, A., Taggart, D. P., and
Wood, K. J. (2010). In vivo preven-
tion of transplant arteriosclerosis by
ex vivo-expanded human regulatory
T cells. Nat. Med. 16, 809–813.
Nishimura, E., Sakihama, T., Setoguchi,
R., Tanaka, K., and Sakaguchi,
S. (2004). Induction of antigen-
speciﬁc immunologic tolerance by
in vivo and in vitro antigen-
speciﬁc expansion of naturally aris-
ing Foxp3+CD25+CD4+ regula-
tory T cells. Int. Immunol. 16,
1189–1201.
Orloff, M. S., DeMara, E. M., Cop-
page, M. L., Leong, N., Fallon, M.
A., Sickel, J., Zuo, X. J., Prehn, J.,
and Jordan, S. C. (1995). Prevention
of chronic rejection and graft arte-
riosclerosis by tolerance induction.
Transplantation 59, 282–288.
Owen, R. D. (1945). Immunogenic con-
sequences of vascular anastomoses
between bovine twins. Science 102,
400–401.
Pearson, T. C., Madsen, J. C., Larsen,
C. P., Morris, P. J., and Wood, K. J.
(1992). Induction of transplantation
tolerance in adults using donor anti-
gen and anti-CD4 monoclonal anti-
body. Transplantation 54, 475–483.
Pilat, N., Baranyi, U., Klaus, C., Jaeckel,
E., Mpofu, N., Wrba, F., Golshayan,
D., Muehlbacher, F., and Wekerle, T.
(2010). Treg-therapy allows mixed
chimerism and transplantation tol-
erance without cytoreductive con-
ditioning. Am. J. Transplant. 10,
751–762.
Pilat, N., Klaus, C., Gattringer, M.,
Jaeckel, E., Wrba, F., Golshayan, D.,
Baranyi, U., and Wekerle, T. (2011).
Therapeutic efﬁcacy of polyclonal
tregs does not require rapamycin in
a low-dose irradiation bone marrow
transplantation model. Transplanta-
tion 92, 280–288.
Pircher, H., Brduscha, K., Steinhoff, U.,
Kasai,M.,Mizuochi, T., Zinkernagel,
R. M., Hengartner, H., Kyewski,
B., and Muller, K. P. (1993). Tol-
erance induction by clonal dele-
tion of CD4+8+thymocytes in vitro
does not require dedicated antigen-
presenting cells. Eur. J. Immunol. 23,
669–674.
www.frontiersin.org December 2011 | Volume 2 | Article 80 | 13
Pasquet et al. Hematopoietic chimerism, Treg, and transplantation tolerance
Pircher, H., Muller, K. P., Kyewski,
B. A., and Hengartner, H. (1992).
Thymocytes can tolerize thymocytes
by clonal deletion in vitro. Int.
Immunol. 4, 1065–1069.
Porcheray, F., Wong, W., Saidman, S. L.,
De Vito, J., Girouard, T. C., Chitten-
den, M., Shaffer, J., Tolkoff-Rubin,
N., Dey, B. R., Spitzer, T. R., Colvin,
R. B., Cosimi, A. B., Kawai, T., Sachs,
D.H., Sykes,M., andZorn,E. (2009).
B-cell immunity in the context of
T-cell tolerance after combined kid-
ney and bone marrow transplanta-
tion in humans. Am. J. Transplant. 9,
2126–2135.
Proietto,A. I., van Dommelen, S., Zhou,
P., Rizzitelli, A., D’Amico, A., Step-
toe, R. J., Naik, S. H., Lahoud, M. H.,
Liu, Y., Zheng, P., Shortman, K., and
Wu, L. (2008). Dendritic cells in the
thymus contribute to T-regulatory
cell induction. Proc. Natl. Acad. Sci.
U.S.A. 105, 19869–19874.
Qin, S. X., Wise, M., Cobbold, S. P.,
Leong, L., Kong, Y. C., Parnes, J. R.,
and Waldmann, H. (1990). Induc-
tion of tolerance in peripheral T cells
with monoclonal antibodies. Eur. J.
Immunol. 20, 2737–2745.
Rammensee, H. G., Kroschewski, R.,
and Frangoulis, B. (1989). Clonal
anergy induced in mature V beta 6+
T lymphocytes on immunizing Mls-
1bmicewithMls-1a expressing cells.
Nature 339, 541–544.
Ribot, J., Enault, G., Pilipenko, S.,
Huchenq, A., Calise, M., Hudrisier,
D., Romagnoli, P., and van Meer-
wijk, J. P. M. (2007). Shaping of
the autoreactive regulatory T cell
repertoire by thymic cortical pos-
itive selection. J. Immunol. 179,
6741–6748.
Ribot, J., Romagnoli, P., and van Meer-
wijk, J. P. M. (2006). Agonist lig-
ands expressed by thymic epithelium
enhance positive selection of regula-
tory T lymphocytes from precursors
with a normally diverse TCR reper-
toire. J. Immunol. 177, 1101–1107.
Rocken,M. (1996). Immune deviation–
the third dimension of nondele-
tional T cell tolerance. Immunol. Rev.
149, 175–194.
Romagnoli, P., Hudrisier, D., and van
Meerwijk, J. P. M. (2002). Prefer-
ential recognition of self-antigens
despite normal thymic deletion of
CD4+CD25+ regulatory T cells. J.
Immunol. 168, 1644–1648.
Romagnoli, P., Hudrisier, D., and van
Meerwijk, J. P. M. (2005). Molecular
signature of recent thymic selection
events on effector and regulatory
CD4+ T lymphocytes. J. Immunol.
175, 5751–5758.
Romagnoli, P., Ribot, J., Tellier, J.,
and van Meerwijk, J. P. M. (2008).
“Thymic and peripheral generation
of CD4+Foxp3+ regulatory T cells,”
in Regulatory T cells and Clinical
Application, ed. S. Jiang (Springer
Science+Business Media), 29–55.
Russell, J.H. (1995).Activation-induced
death of mature T cells in the reg-
ulation of immune responses. Curr.
Opin. Immunol. 7, 382–388.
Russell, P. S., Chase, C. M., Sykes, M.,
Ito, H., Shaffer, J., and Colvin, R. B.
(2001). Tolerance,mixed chimerism,
and chronic transplant arteriopathy.
J. Immunol. 167, 5731–5740.
Sakaguchi, S., Ono, M., Setoguchi,
R., Yagi, H., Hori, S., Fehervari,
Z., Shimizu, J., Takahashi, T., and
Nomura, T. (2006). Foxp3+ CD25+
CD4+ natural regulatory T cells
in dominant self-tolerance and
autoimmune disease. Immunol. Rev.
212, 8–27.
Sakaguchi, S., Sakaguchi, N., Asano,
M., Itoh, M., and Toda, M. (1995).
Immunologic self-tolerance main-
tained by activated T cells expressing
IL-2 receptor alpha-chains (CD25).
Breakdown of a single mecha-
nism of self-tolerance causes various
autoimmune diseases. J. Immunol.
155, 1151–1164.
Scandling, J. D., Busque, S., Dejbakhsh-
Jones, S., Benike, C., Millan, M. T.,
Shizuru, J. A., Hoppe, R. T., Lowsky,
R., Engleman, E. G., and Strober,
S. (2008). Tolerance and chimerism
after renal and hematopoietic-cell
transplantation. N. Engl. J.Med. 358,
362–368.
Scheid, M., Boyse, E. A., Carswell, E.
A., and Old, L. J. (1972). Serolog-
ically demonstrable alloantigens of
mouse epidermal cells. J. Exp. Med.
135, 938–955.
Shevach, E. M., DiPaolo, R. A., Ander-
sson, J., Zhao, D. M., Stephens, G.
L., and Thornton, A. M. (2006).
The lifestyle of naturally occur-
ring CD4+ CD25+ Foxp3+ regu-
latory T cells. Immunol. Rev. 212,
60–73.
Shirasugi, N., Adams, A. B., Durham,
M. M., Lukacher, A. E., Xu, H., Rees,
P., Cowan, S. R., Williams, M. A.,
Pearson, T. C., and Larsen, C. P.
(2002). Prevention of chronic rejec-
tion in murine cardiac allografts:
a comparison of chimerism- and
nonchimerism-inducing costim-
ulation blockade-based tolerance
induction regimens. J. Immunol.
169, 2677–2684.
Slavin, S., Reitz, B., Bieber, C. P., Kaplan,
H. S., and Strober, S. (1978). Trans-
plantation tolerance in adult rats
using total lymphoid irradiation:
permanent survival of skin, heart,
and marrow allografts. J. Exp. Med.
147, 700–707.
Slupsky, J. R., Kalbas, M., Willuweit,
A., Henn, V., Kroczek, R. A., and
Muller-Berghaus, G. (1998). Acti-
vated platelets induce tissue fac-
tor expression on human umbili-
cal vein endothelial cells by liga-
tion of CD40. Thromb. Haemost. 80,
1008–1014.
Sorof, J. M., Koerper, M. A., Por-
tale, A. A., Potter, D., DeSantes,
K., and Cowan, M. (1995). Renal
transplantation without chronic
immunosuppression after T cell-
depleted, HLA-mismatched bone
marrow transplantation. Transplan-
tation 59, 1633–1635.
Spitzer, T. R., Delmonico, F., Tolkoff-
Rubin, N., McAfee, S., Sackstein,
R., Saidman, S., Colby, C., Sykes,
M., Sachs, D. H., and Cosimi, A.
B. (1999). Combined histocompat-
ibility leukocyte antigen-matched
donor bone marrow and renal trans-
plantation for multiple myeloma
with end stage renal disease: the
induction of allograft tolerance
through mixed lymphohematopoi-
etic chimerism. Transplantation 68,
480–484.
Steinmuller, D., and Lofgreen, J. S.
(1974). Differential survival of skin
and heart allografts in radiation chi-
maeras provides further evidence
for Sk histocompatibility antigen.
Nature 248, 796–797.
Stone, W. H., Cragle, R. G., Johnson, D.
F., Bacon, J. A., Bendel, S., andKorda,
N. (1971). Long-term observations
of skin grafts between chimeric cattle
twins. Transplantation 12, 421–428.
Stone, W. H., Cragle, R. G., Swanson, E.
W., and Brown, D. G. (1965). Skin
grafts: delayed rejection between
pairs of cattle twins showing ery-
throcyte chimerism. Science 148,
1335–1336.
Streilein, J. W. (1991). Neonatal toler-
ance of H-2 alloantigens. Procuring
graft acceptance the “old-fashioned”
way. Transplantation 52, 1–10.
Streilein, J. W., and Klein, J. (1977).
Neonatal tolerance induction across
regions of H-2 complex. J. Immunol.
119, 2147–2150.
Strober, S., Modry, D. L., Hoppe, R.
T., Pennock, J. L., Bieber, C. P.,
Holm, B. I., Jamieson, S. W., Stin-
son, E. B., Schroder, J., and Suo-
malainen, H. (1984). Induction of
speciﬁc unresponsiveness to heart
allografts in mongrel dogs treated
with total lymphoid irradiation and
antithymocyte globulin. J. Immunol.
132, 1013–1018.
Thomas, J., Carver, M., Cunningham,
P., Park, K., Gonder, J., and Thomas,
F. (1987). Promotion of incom-
patible allograft acceptance in rhe-
sus monkeys given posttransplant
antithymocyte globulin and donor
bone marrow. I. In vivo parame-
ters and immunohistologic evidence
suggesting microchimerism. Trans-
plantation 43, 332–338.
Thomas, J. M., Carver, F. M., Foil, M. B.,
Hall,W. R.,Adams,C., Fahrenbruch,
G. B., and Thomas, F. T. (1983).
Renal allograft tolerance induced
with ATG and donor bone marrow
in outbred rhesus monkeys. Trans-
plantation 36, 104–106.
Thornton, A. M., and Shevach, E. M.
(2000). Suppressor effector func-
tion of CD4+CD25+ immunoregu-
latory T cells is antigen nonspeciﬁc.
J. Immunol. 164, 183–190.
Tomita, Y., Khan, A., and Sykes, M.
(1994). Role of intrathymic clonal
deletion and peripheral anergy in
transplantation tolerance induced
by bone marrow transplantation in
mice conditioned with a nonmye-
loablative regimen. J. Immunol. 153,
1087–1098.
Tomita, Y., Mayumi, H., Eto, M.,
and Nomoto, K. (1990a). Impor-
tance of suppressor T cells in
cyclophosphamide-induced tol-
erance to the non-H-2-encoded
alloantigens. Is mixed chimerism
really required in maintaining a skin
allograft tolerance? J. Immunol. 144,
463–473.
Tomita, Y., Nishimura, Y., Harada, N.,
Eto, M., Ayukawa, K., Yoshikai,
Y., and Nomoto, K. (1990b). Evi-
dence for involvement of clonal
anergy in MHC class I and class
II disparate skin allograft tolerance
after the termination of intrathymic
clonal deletion. J. Immunol. 145,
4026–4036.
Trentin, J. J. (1956). Mortality and
skin transplantability in x-irradiated
mice receiving isologous, homolo-
gous or heterologous bone mar-
row. Proc. Soc. Exp. Biol. Med. 92,
688–693.
Tsang, J. Y., Tanriver, Y., Jiang, S.,
Xue, S. A., Ratnasothy, K., Chen,
D., Stauss, H. J., Bucy, R. P., Lom-
bardi, G., and Lechler, R. (2008).
Conferring indirect allospeciﬁcity
on CD4CD25 Tregs by TCR gene
transfer favors transplantation tol-
erance in mice. J. Clin. Invest. 118,
3619–3628.
van Meerwijk, J. P. M., and MacDon-
ald, H. R. (1999). In vivo T lym-
phocyte tolerance in the absence
of thymic clonal deletion mediated
by haematopoietic cells. Blood 93,
3856–3862.
Van Parijs, L., Ibraghimov, A., and
Abbas,A. K. (1996). The roles of cos-
timulation and Fas in T cell apopto-
sis and peripheral tolerance. Immu-
nity 4, 321–328.
Frontiers in Immunology | Immunological Tolerance December 2011 | Volume 2 | Article 80 | 14
Pasquet et al. Hematopoietic chimerism, Treg, and transplantation tolerance
Waldmann, H. (2010). Tolerance: an
overview and perspectives. Nat. Rev.
Nephrol. 6, 569–576.
Walker, L. S., and Abbas, A. K. (2002).
The enemy within: keeping self-
reactive T cells at bay in the periph-
ery. Nat. Rev. Immunol. 2, 11–19.
Watanabe, N., Wang, Y. H., Lee, H.
K., Ito, T., Wang, Y. H., Cao, W.,
and Liu, Y. J. (2005). Hassall’s cor-
puscles instruct dendritic cells to
induce CD4+CD25+ regulatory T
cells in human thymus. Nature 436,
1181–1185.
Wekerle, T., Kurtz, J., Ito, H., Ron-
quillo, J. V., Dong,V., Zhao, G., Shaf-
fer, J., Sayegh, M. H., and Sykes,
M. (2000). Allogeneic bone marrow
transplantation with co-stimulatory
blockade induces macrochimerism
and tolerance without cytoreduc-
tive host treatment. Nat. Med. 6,
464–469.
Wekerle, T., Kurtz, J., Sayegh, M., Ito,
H., Wells, A., Bensinger, S., Shaffer,
J., Turka, L., and Sykes, M. (2001).
Peripheral deletion after bone mar-
row transplantation with costimula-
tory blockade has features of both
activation-induced cell death and
passive cell death. J. Immunol. 166,
2311–2316.
Wekerle, T., Sayegh, M. H., Hill, J.,
Zhao, Y., Chandraker, A., Swenson,
K. G., Zhao, G., and Sykes, M.
(1998). Extrathymic T cell deletion
and allogeneic stem cell engraftment
induced with costimulatory block-
ade is followed by central T cell tol-
erance. J. Exp. Med. 187, 2037–2044.
Wekerle,T., and Sykes,M. (1999).Mixed
chimerism as an approach for the
induction of transplantation toler-
ance. Transplantation 68, 459–467.
Welsh, R. M., Markees, T. G., Woda,
B. A., Daniels, K. A., Brehm, M.
A., Mordes, J. P., Greiner, D. L.,
and Rossini, A. A. (2000). Virus-
induced abrogation of transplanta-
tion tolerance induced by donor-
speciﬁc transfusion and anti-CD154
antibody. J. Virol. 74, 2210–2218.
Williams, M. A., Tan, J. T., Adams,
A. B., Durham, M. M., Shirasugi,
N., Whitmire, J. K., Harrington, L.
E., Ahmed, R., Pearson, T. C., and
Larsen, C. P. (2001). Characteriza-
tion of virus-mediated inhibition
of mixed chimerism and allospe-
ciﬁc tolerance. J. Immunol. 167,
4987–4995.
Wirnsberger, G., Mair, F., and Klein,
L. (2009). Regulatory T cells dif-
ferentiation of thymocytes does
not require a dedicated antigen-
presenting cell but is under T
cell-intrinsic developmental con-
trol. Proc. Natl. Acad. Sci. U.S.A.
doi:10.1073/pnas.0901877106.
Wood, P. J., and Streilein, J. W. (1982).
Ontogeny of acquired immunolog-
ical tolerance to H-2 alloantigens.
Eur. J. Immunol. 12, 188–194.
Wren, S. M., Hronakes, M. L., and
Ildstad, S. T. (1993). CD4+ T
cells, but not CD8+ T cells,
mediate the breaking of toler-
ance in mixed allogeneic chimeras
(B10+B10.BR–>B10). Transplan-
tation 55, 1382–1389.
Wu, L., and Shortman, K. (2005). Het-
erogeneity of thymic dendritic cells.
Semin. Immunol. 17, 304–312.
Wu, O., Levy, A. R., Briggs, A., Lewis,
G., and Jardine, A. (2009). Acute
rejection and chronic nephropa-
thy: a systematic review of the
literature. Transplantation 87,
1330–1339.
Yamada, K., Choo, J. K., Allan, J. S.,
Erhorn,A. E.,Menard,M. T.,Mawu-
lawde, K., Slisz, J. K., Aretz, H.
T., Shimizu, A., Sachs, D. H., and
Madsen, J. C. (1999). The effect of
thymectomy on tolerance induction
and cardiac allograft vasculopathy
in a miniature swine heart/kidney
transplantation model. Transplanta-
tion 68, 485–491.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 20 July 2011; accepted: 05
December 2011; published online: 28
December 2011.
Citation: Pasquet L, Joffre O, Santo-
laria T and van Meerwijk JPM (2011)
Hematopoietic chimerism and trans-
plantation tolerance: a role for regula-
tory T cells. Front. Immun. 2:80. doi:
10.3389/ﬁmmu.2011.00080
This article was submitted to Frontiers in
Immunological Tolerance, a specialty of
Frontiers in Immunology.
Copyright © 2011 Pasquet , Joffre, San-
tolaria and van Meerwijk. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
www.frontiersin.org December 2011 | Volume 2 | Article 80 | 15
